Alladapt Immunotherapeutics

company

About

Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy.

  • 11 - 50

Details

Last Funding Type
Debt Financing
Last Funding Money Raised
$50M
Industries
Biotechnology
Founded date
Jan 1, 2018
Number Of Employee
11 - 50
Operating Status
Active

Alladapt Immunotherapeutics is a privately held biopharmaceutical company developing prescription therapeutics targeting food allergy. The Company’s lead program, ADP101, is being advanced as a broad spectrum oral immunotherapy treatment to mitigate food allergy triggered by single or multiple proteins from an expansive set of common allergens.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$50M
Alladapt Immunotherapeutics has raised a total of $50M in funding over 2 rounds. Their latest funding was raised on Aug 30, 2022 from a Debt Financing round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 30, 2022 Debt Financing $50M 1 Hercules Capital Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Alladapt Immunotherapeutics is funded by 1 investors. Hercules Capital are the most recent investors.
Investor Name Lead Investor Funding Round
Hercules Capital Yes Debt Financing